Poorly Differentiated Chordoma
specificA rare, aggressive type of chordoma characterized by loss of SMARCB1 expression. It affects children and occasionally young adults. Females are affected twice as frequently as males. It usually arises in the axial skeleton. It is composed of sheets or nests of malignant epithelioid cells with abundant eosinophilic cytoplasm. The prognosis is poor.
13
Centers
13
Active Trials
—
Cancer Funding
Top Centers for Poorly Differentiated Chordoma(13)
Ranked by research excellence score (trials · grants · publications). Methodology →
| # | Center | Score |
|---|---|---|
| 1 | Memorial Sloan Kettering Cancer CenterNew York, NY NCI Comprehensive Active Research Program | 53.8 |
| 2 | Dana-Farber Cancer InstituteBoston, MA NCI Comprehensive Active Research Program | 53.8 |
| 3 | Stanford Cancer InstitutePalo Alto, CA NCI Comprehensive Active Research Program | 53.8 |
| 4 | Vanderbilt-Ingram Cancer CenterNashville, TN NCI Comprehensive Active Research Program | 53.8 |
| 5 | Herbert Irving Comprehensive Cancer CenterNew York, NY NCI Comprehensive Active Research Program | 53.8 |
| 6 | Duke Cancer InstituteDurham, NC NCI Comprehensive Active Research Program | 53.8 |
| 7 | NCI Comprehensive Active Research Program | 53.8 |
| 8 | Masonic Cancer CenterMinneapolis, MN NCI Comprehensive Active Research Program | 53.8 |
| 9 | University of Colorado Cancer CenterAurora, CO NCI Comprehensive Active Research Program | 53.8 |
| 10 | Medical College of Wisconsin Cancer CenterMilwaukee, WI Active Research Program | 53.8 |
| 11 | University of Illinois Cancer CenterChicago, IL Active Research Program | 53.8 |
| 12 | Boston University Cancer CenterBoston, MA Active Research Program | 53.8 |
| 13 | University of Cincinnati Cancer CenterCincinnati, OH Active Research Program | 53.8 |
Research tier badges reflect trial volume, NIH grant funding, and publication impact — not clinical outcomes or patient satisfaction. Learn about our methodology →